| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalaris Therapeutics, Inc. (KLRS) has 2 insiders with recent SEC Form 4 filings, including 0 buys and 13 sells. KLRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 2.22M | $10.50M | - | |
| CFO | 235.0K | $1.11M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 3, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 1,597 | $0.80 | $1,271.21 | -2.1% | +0.3% | -68.2% | |
| May 3, 2024 | Sinha Vikas84 | See Remarks | Sell | 4,957 | $0.80 | $3,945.77 | -0.4% | +0.3% | -68.2% | |
| May 3, 2024 | Miller Edward82 | General Counsel | Sell | 2,311 | $0.80 | $1,839.56 | -1.0% | +0.3% | -68.2% | |
| Apr 22, 2024 | Miller Edward82 | General Counsel | Sell | 1,383 | $0.75 | $1,037.63 | -0.3% | -0.6% | -61.5% | |
| Apr 22, 2024 | Sinha Vikas84 | See Remarks | Sell | 3,378 | $0.75 | $2,534.41 | -0.1% | -0.6% | -61.5% | |
| Apr 22, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 953 | $0.75 | $715.03 | -0.6% | -0.6% | -61.5% | |
| Apr 19, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 9,601 | $0.75 | $7,206.51 | -1.2% | +1.3% | -61.7% | |
| Apr 2, 2024 | Miller Edward82 | General Counsel | Sell | 368 | $0.77 | $284.10 | -0.2% | -4.9% | -54.3% | |
| Apr 2, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 1,533 | $0.77 | $1,183.48 | -0.2% | -4.9% | -54.3% | |
| Apr 2, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 281 | $0.77 | $216.93 | -0.4% | -4.9% | -54.3% |